文献速递免疫规划卫生政策与健康促进

2000-2018年全球风疹及先天性风疹综合征控制与消除进展

Progress Toward Rubella and Congenital Rubella Syndrome Control and Elimination - Worldwide, 2000-2018.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2019-10-04

本报告利用WHO免疫与监测数据,总结2000年与2012年至2018年全球风疹及先天性风疹综合征(CRS)控制与消除进展。含风疹疫苗(RCV)免疫规划的国家从2000年99个(52%,191国)增至2018年168个(87%,194国),2018年全球69%婴儿接种风疹疫苗,81个(42%)国家已验证消除风疹。

要点

  • 含RCV免疫规划国家从2000年99个(52%)增至2018年168个(87%)。
  • 2018年全球69%婴儿接种风疹疫苗,81个(42%)国家已验证消除风疹。
  • 未设消除目标的WHO非洲区和东地中海区应考虑设立目标。

核心结论

  • 为进一步控制和消除风疹并缩小公平差距,所有国家引入RCV很重要;已引入RCV的国家可通过高接种覆盖率和风疹及CRS监测实现并维持消除。
  • 尚未设立消除目标的WHO非洲区和东地中海区应考虑设立目标。

研究设计与样本

  • 利用WHO免疫与监测数据,总结2000年(加速麻疹控制活动启动)和2012年(加速风疹控制活动启动)至2018年(最新数据)全球风疹及CRS控制与消除进展。

主要发现

  • WHO成员国中含RCV免疫规划的国家从2000年99个(52%,191国)增至2018年168个(87%,194国)。
  • 2018年全球69%的婴儿接种了风疹疫苗。
  • 81个(42%)国家已验证消除风疹。

关键数值与推荐

  • 2011年WHO更新RCV使用指南,推荐利用加速麻疹消除活动的机会引入RCV。
  • 全球疫苗行动计划2011-2020(GVAP)目标为到2020年至少五个WHO区域实现消除风疹。

临床怎么用

  • 所有国家引入RCV对进一步控制和消除风疹及缩小公平差距很重要。
  • 已引入RCV的国家可通过高接种覆盖率和风疹及CRS监测实现并维持消除。
  • WHO非洲区和东地中海区应考虑设立风疹消除目标。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rubella is a leading cause of vaccine-preventable birth defects. Although rubella virus infection usually causes a mild febrile rash illness in children and adults, infection during pregnancy, especially during the first trimester, can result in miscarriage, fetal death, stillbirth, or a constellation of birth defects known as congenital rubella syndrome (CRS). A single dose of rubella-containing vaccine (RCV) can provide lifelong protection (1). In 2011, the World Health Organization (WHO) updated guidance on the use of RCV and recommended capitalizing on the accelerated measles elimination activities as an opportunity to introduce RCV (1). The Global Vaccine Action Plan 2011-2020 (GVAP) includes a target to achieve elimination of rubella in at least five of the six WHO regions by 2020 (2). This report on the progress toward rubella and CRS control and elimination updates the 2017 report (3), summarizing global progress toward the control and elimination of rubella and CRS from 2000 (the initiation of accelerated measles control activities) and 2012 (the initiation of accelerated rubella control activities) to 2018 (the most recent data) using WHO immunization and surveillance data. Among WHO Member States,* the number with RCV in their immunization schedules has increased from 99 (52% of 191) in 2000 to 168 (87% of 194) in 2018†; 69% of the world's infants were vaccinated against rubella in 2018. Rubella elimination has been verified in 81 (42%) countries. To make further progress to control and eliminate rubella, and to reduce the equity gap, introduction of RCV in all countries is important. Likewise, countries that have introduced RCV can achieve and maintain elimination with high vaccination coverage and surveillance for rubella and CRS. The two WHO regions that have not established an elimination goal (African [AFR] and Eastern Mediterranean [EMR]) should consider establishing a goal.§.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Grant GB, Desai S, Dumolard L, et al. Progress Toward Rubella and Congenital Rubella Syndrome Control and Elimination - Worldwide, 2000-2018. MMWR Morb Mortal Wkly Rep. 2019. PMID: 31581161. doi:10.15585/mmwr.mm6839a5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。